Strong Momentum in Pharmaceuticals

Roche’s latest financial report highlights the strength of its pharmaceutical business, which remains the company’s primary growth engine. For the first nine months of 2025, group sales reached CHF 45.9 billion, representing a 7% increase at constant exchange rates compared to the same period last year. The Pharmaceuticals Division contributed CHF 35.6 billion — up 9% at CER — supported by sustained demand for treatments across oncology, immunology, and neuroscience.

Drugs such as Vabysmo (used to treat eye diseases), Ocrevus (for multiple sclerosis), and Hemlibra (for hemophilia A) posted particularly strong growth. Roche also reported improving performance in its newer products, which are successfully offsetting revenue declines from older medicines facing biosimilar competition.

Upgraded Forecast Reflects Confidence in Future Growth

Encouraged by its strong nine-month results, Roche raised its full-year 2025 outlook, forecasting mid-single-digit sales growth and core EPS growth in the high single to low double digits at constant exchange rates. The company also reaffirmed plans to increase its annual dividend, reflecting management’s confidence in profitability and cash generation.

Roche’s decision to revise its outlook upward underscores the success of its innovation-driven strategy. Its expanding late-stage pipeline, which includes multiple therapies across oncology and rare diseases, is expected to sustain long-term revenue growth. The company also continues to invest heavily in biotechnology and precision medicine, positioning itself strongly against competitors such as Novartis and AstraZeneca.

Diagnostics Unit Remains Stable Despite Pricing Challenges

While pharmaceuticals were the main driver of growth, Roche’s Diagnostics Division reported modest sales of CHF 10.3 billion, up 1% at CER but down 4% in Swiss francs due to pricing pressure, particularly in China. The company noted resilience in areas such as molecular diagnostics and pathology, which partially offset weaker results in other segments.

Roche acknowledged that pricing reforms in Asia remain a headwind but reaffirmed its commitment to expanding its diagnostics portfolio through technological innovation and digital solutions. This segment continues to play a key role in supporting Roche’s long-term vision of combining therapeutics and diagnostics — an integrated approach known as “personalized healthcare.”

Looking Ahead — Innovation to Drive Long-Term Strength

Roche’s raised forecast suggests renewed optimism for 2025 and beyond. With a broad and diversified pipeline, the company is strategically positioned to maintain leadership in critical therapeutic areas while navigating global pricing and currency pressures.

Investors will be closely watching the commercial rollout of new drugs, progress in late-stage clinical trials, and the company’s diagnostics recovery trajectory in the coming quarters. If Roche maintains its current momentum, its strong innovation portfolio could sustain double-digit profit growth and reinforce its reputation as one of the world’s most stable and forward-looking pharmaceutical leaders.